Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 1 - 10 of 47

Investigator:

Carlos Cruchaga

Title:

Identification of mutation-specific networks. Amended

Date of Request:

11/02/2017

Status:

Pending

ID:

DIAN-T1710

Aim 1:

To generate RNA-seq data from brain tissue from DIAN participants (mutation carriers and non-carriers)

Aim 2:

To identify genes differentially expressed or spliced in mutation carriers vs LOAD, and vs controls

Aim 3:

To identify gene and mutation-specific networks and pathways

Investigator:

Mikael Simons

Title:

Lipidomics study of preclinical plasma biomarkers for Alzheimer´s disease

Date of Request:

10/11/2017

Status:

Pending

ID:

DIAN T1709

Aim 1:

Establish a preclinical biomarker for AD

Aim 2:

Determine lipid profiles in preclinical AD

Aim 3:

Compare lipid profiles in DIAN and Framingham

Aim 4:

Determine longitudinal changes of lipid profiles during disease

Investigator:

Laurent Roybon

Title:

AD pathology in advanced cellular models

Date of Request:

09/10/2017

Status:

Pending review

ID:

DIAN-T1708

Aim 1:

Generation of iPSCs from AD patient fibroblasts

Aim 2:

Differentiation of AD iPSCs into neurons

Aim 3:

Analysis of cellular networks dysfunction

Investigator:

Makoto Ishii

Title:

Leptin and metabolic signaling in autosomal dominant Alzheimer’s disease

Date of Request:

09/07/2017

Status:

Pending review

ID:

DIAN-T1707

Aim 1:

To determine if alterations in levels of plasma leptin and related metabolic markers are evident in cognitively normal subjects with autosomal dominant Alzheimer’s disease

Aim 2:

To determine if alterations in plasma leptin levels and related metabolic markers correlate with changes in Alzheimer’s disease biomarkers in subjects with autosomal dominant Alzheimer’s disease

Aim 3:

To determine if levels of plasma leptin and related metabolic markers correlate with worsening Alzheimer’s disease biomarkers and progression of cognitive decline over time (age) in subjects with autosomal dominant Alzheimer’s disease

Investigator:

Steve Wagner, Ph.D.

Title:

Preclinical validation of target engagement for a potent disease modifying therapeutic for AD in dominantly inherited EOFAD patient induced human neurons

Date of Request:

08/16/2017

ID:

DIAN-T1706

Aim 1:

Demonstrate target engagement against human neurons harboring EOFAD mutations

Aim 2:

Evaluation of the effects of GSMs in hiPSC in-vitro systems on downstream AD pathways

Investigator:

Randall Bateman

Title:

DIAN-ADNI comparison study

Date of Request:

2/23/2017

ID:

DIAN-T1703

Aim 1:

In LOAD and ADAD determine whether both groups demonstrate initial cerebral amyloidosis that is followed by the development of neurodegeneration prior to onset of AD symptoms

Aim 2:

Characterize similarities and any differences in AD phenotypes between LOAD and ADAD

Aim 3:

In both LOAD and ADAD, determine whether there is a pattern of disease progression that is marked by intra-individual global cognitive and functional decline that culminates in death

Aim 4:

Examine the contribution of age to the dementing process.

Investigator:

Cruchaga

Title:

Genetic architecture of CSF biomarker levels in ADAD

Date of Request:

2/27/2017

ID:

DIAN-T1702

Aim 1:

To identify genetic variants and genes associated with CSF biomaker levels in DIAN

Aim 2:

To determine the overlap in the genetic architecture of late-onset sporadic AD with ADAD

Aim 3:

To identify protective and modifiers variants for AD

Investigator:

Alison Goate

Title:

Characterization of γ-Secretase in fibroblasts derived from FAD patients harboring PSEN1or PSEN2 mutations

Date of Request:

3/9/2017

ID:

DIAN-T1704

Aim 1:

Determine in vitro γ-secretase activity for Aβ40 and Aβ42 production using fibroblast cell membranes

Aim 2:

Characterize the γ-secretase complexes in fibroblast cell membranes

Aim 3:

Examine the sensitivity of various modulators and inhibitors to γ-secretase in fibroblast cell membranes

Investigator:

Eric McDade

Title:

Comprehensive CSF tau profiling in DIAN using a novel mass spectrometry

Date of Request:

5/10/2017

ID:

DIAN-T1705

Aim 1:

Determine stage of the disease where additional p-tau isoforms (particularly p-tau Thr 217) begin to differ between MC and NC based on EYO and Aβ status, and compare this to the currently used immunoassay measures of tau and p-tau181.

Aim 2:

Determine longitudinal change (quantitative change / mean and SD) of the various p-tau isoforms identified as it relates to disease stage and how this compares to the currently used immunoassay measures of tau and p-tau181.

Aim 3:

Assess the association between baseline and longitudinal CSF MS p-tau isoforms and other measures of disease (neuroimaging- FDG �PET, MRI volumetrics and tau �PET; clinical- CDR, cognition).

Aim 4:

Compare the comprehensive CSF tau profile identified in DIAN with that completed and underway in sAD at Washington University by Drs. Barth�lemy and Bateman.

Investigator:

Bernadino Ghetti

Title:

Neuropathological findings of brains of persons with familial AD (FAD) due to the A431E PSEN1 mutation

Date of Request:

12/5/2011

Status:

A

ID:

DIAN-T1102

Aim 1:

To thoroughly characterize and describe the neuropathological findings of 11 brains of persons with familial AD (FAD) due to the A431E PSEN1 mutation.

Aim 2:

To correlate pathological findings with clinical findings in these patients.

Aim 3:

To explain specific clinical and imaging features of the A431E mutation by quantifying aspects of the neuropathology.